NEW YORK ( TheStreet) -- Transition Therapeutics (Nasdaq: TTHI) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada. Transition has a market cap of $49.7 million and is part of the health care sector and drugs industry. Shares are up 46.4% year to date as of the close of trading on Tuesday.
More from Markets
Chewy Shares Fall After Hours as Second-Quarter Loss Widens
The online pet food retailer reported a second-quarter loss of 21 cents vs. expectations of 11 cents.
Adobe Shares Fall on Weak Guidance, Though Earnings Beat
Adobe investors were disappointed with management's guidance, which missed analysts estimates.
Warning Signs Are Looming for Cyclicals, Industrials -- Time to Get Defensive?
Here's your investment strategy, if you're defensive.
Stocks Finish Up Wall Street Awaits Fed Decision on Rates, Oil Prices Slump
Stocks end in positive territory Tuesday as investors proceed with caution as the Federal Reserve's two-day rate-setting meeting kicks off.